Filing Flows › Voyager Therapeutics (VYGR) › Q2 2026 › vs Q1 2026
Voyager Therapeutics (VYGR) Q2 2026 vs Q1 2026 (quarter over quarter)
Voyager Therapeutics's revenue rose $572K (+22%) from $2.6M in Q1 2026 to $3.2M in Q2 2026.
Voyager Therapeutics, Q2 2026: revenue $3.2M (-39% year over year), operating margin -833.9%, net loss $24.5M, operating cash flow −$25.8M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $3.2M | $2.6M | $572K | +22% |
| Other income, net | $1.9M | $2.3M | −$408K | -17% |
| Net loss | $24.5M | $27.9M | −$3.5M | -12% |
| Costs & expenses | $29.6M | $32.9M | −$3.3M | -10% |
| Operating costs | $29.6M | $32.9M | −$3.3M | -10% |
| Income tax | $20K | $14K | $6K | +43% |
| Research & development | $22.0M | $24.6M | −$2.6M | -10% |
| General & admin | $7.5M | $8.3M | −$745K | -9% |
| Operating cash sources | $29.2M | $36.8M | −$7.7M | -21% |
| Depreciation | $908K | $932K | −$24K | -3% |
| Share-based compensation | $2.4M | $2.5M | −$55K | -2% |
| Cash used in operations | $25.8M | $33.4M | −$7.6M | -23% |
| Net loss absorbed | $24.5M | $27.9M | −$3.5M | -12% |
| Working capital & other | $4.7M | $8.9M | −$4.2M | -47% |
Questions
How much did Voyager Therapeutics's revenue grow quarter over quarter in Q2 2026?
Voyager Therapeutics's revenue rose $572K (+22%) from $2.6M in Q1 2026 to $3.2M in Q2 2026.